Literature DB >> 28320914

Two Strikes and You're Out? The Pathogenic Interplay of Coinhibitor Deficiency and Lymphopenia-Induced Proliferation.

Kristofor K Ellestad1,2, Colin C Anderson1,2,3,4.   

Abstract

Lymphopenia-induced proliferation (LIP) occurs when resources for T cell survival in a host are in excess. LIP has been associated with the development of inflammatory disease in situations where an additional disease-predisposing cofactor is present during LIP. This has led to the view of LIP-driven autoimmunity as a two hit model; however, not all cofactors have equal ability to precipitate autoimmunity and we have recently shown that in some circumstances, such as the absence of the coinhibitory molecule PD-1, additional hits are required. Herein we review factors controlling LIP, including coinhibitory molecules and other attenuators of TCR signaling, with a focus on their contribution to LIP-driven autoimmunity. Rather than viewing LIP-associated autoimmunity as an n-hit model, we suggest a more quantitative view of lymphopenia with respect to the factors that promote LIP as a tool to predict autoimmune potential and to inform tumor immunotherapy approaches.
Copyright © 2017 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28320914     DOI: 10.4049/jimmunol.1601884

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

1.  Prevalence and pathogenicity of autoantibodies in patients with idiopathic CD4 lymphopenia.

Authors:  Ainhoa Perez-Diez; Chun-Shu Wong; Xiangdong Liu; Harry Mystakelis; Jian Song; Yong Lu; Virginia Sheikh; Jeffrey S Bourgeois; Andrea Lisco; Elizabeth Laidlaw; Cornelia Cudrici; Chengsong Zhu; Quan-Zhen Li; Alexandra F Freeman; Peter R Williamson; Megan Anderson; Gregg Roby; John S Tsang; Richard Siegel; Irini Sereti
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

2.  Human neonatal thymectomy induces altered B-cell responses and autoreactivity.

Authors:  Theo van den Broek; Asaf Madi; Eveline M Delemarre; Alvin W L Schadenberg; Kiki Tesselaar; José A M Borghans; Stefan Nierkens; Frank A Redegeld; Henny G Otten; Maura Rossetti; Salvatore Albani; Rachel Sorek; Irun R Cohen; Nicolaas J G Jansen; Femke van Wijk
Journal:  Eur J Immunol       Date:  2017-09-06       Impact factor: 5.532

Review 3.  Immune Equilibrium Depends on the Interaction Between Recognition and Presentation Landscapes.

Authors:  Daniil Shevyrev; Valeriy Tereshchenko; Vladimir Kozlov
Journal:  Front Immunol       Date:  2021-07-30       Impact factor: 7.561

4.  Prognostic Significance of NLR About NETosis and Lymphocytes Perturbations in Localized Renal Cell Carcinoma With Tumor Thrombus.

Authors:  Bingqing Shang; Liping Guo; Rongfang Shen; Chuanzhen Cao; Ruiyang Xie; Weixing Jiang; Li Wen; Xingang Bi; Hongzhe Shi; Shan Zheng; Changling Li; Jianhui Ma; Kaitai Zhang; Lin Feng; Jianzhong Shou
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

5.  Loss of thymic function promotes EAE relapse in anti-CD52-treated mice.

Authors:  Adeolu O Adegoke; Jiaxin Lin; Colin C Anderson
Journal:  Curr Res Immunol       Date:  2022-03-08

6.  PD-1 Controls Tonic Signaling and Lymphopenia-Induced Proliferation of T Lymphocytes.

Authors:  Kristofor K Ellestad; Jiaxin Lin; Louis Boon; Colin C Anderson
Journal:  Front Immunol       Date:  2017-10-12       Impact factor: 7.561

7.  Prior to Peripheral Tolerance, Newly Generated CD4 T Cells Maintain Dangerous Autoimmune Potential: Fas- and Perforin-Independent Autoimmunity Controlled by Programmed Death-1.

Authors:  Kristofor K Ellestad; Govindarajan Thangavelu; Yohannes Haile; Jiaxin Lin; Louis Boon; Colin C Anderson
Journal:  Front Immunol       Date:  2018-01-24       Impact factor: 7.561

Review 8.  Dose dependence of treatment-related adverse events for immune checkpoint inhibitor therapies: a model-based meta-analysis.

Authors:  Boris Shulgin; Yuri Kosinsky; Andrey Omelchenko; Lulu Chu; Ganesh Mugundu; Sergey Aksenov; Rodrigo Pimentel; Garrett DeYulia; Geoffrey Kim; Kirill Peskov; Gabriel Helmlinger
Journal:  Oncoimmunology       Date:  2020-05-21       Impact factor: 8.110

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.